scholarly journals Distortion product otoacoustic emission fine structure as an early hearing loss predictor

2006 ◽  
Vol 120 (5) ◽  
pp. 3123-3123
Author(s):  
Karen Reuter ◽  
Dorte Hammersho/i
2013 ◽  
Vol 127 (10) ◽  
pp. 952-956 ◽  
Author(s):  
A Goyal ◽  
P P Singh ◽  
A Vashishth

AbstractObjectives:This study aimed to: understand the effect that high intensity noise associated with drilling (during otological surgery) has on hearing in the contralateral ear; determine the nature of hearing loss, if any, by establishing whether it is temporary or persistent; and examine the association between hearing loss and various drill parameters.Methods:A prospective clinical study was carried out at a tertiary centre. Thirty patients with unilateral cholesteatoma and normal contralateral hearing were included. Patients were evaluated pre-operatively and for five days following surgery using high frequency pure tone audiometry, and low and high frequency transient evoked and distortion product otoacoustic emission testing.Results:The findings revealed statistically significant changes in distortion product otoacoustic emissions at high frequencies (p = 0.016), and in transient evoked otoacoustic emissions at both low and high frequencies (p = 0.035 and 0.021, respectively). There was a higher statistical association between otoacoustic emission changes and cutting burrs compared with diamond burrs.Conclusion:Drilling during mastoid surgery poses a threat to hearing in the contralateral ear due to noise and vibration conducted transcranially.


2015 ◽  
Vol 137 (4) ◽  
pp. 2408-2409
Author(s):  
James D. Lewis ◽  
Emily C. Clark ◽  
Judy G. Kopun ◽  
Walt Jesteadt ◽  
Stephen T. Neely ◽  
...  

2017 ◽  
Vol 131 (11) ◽  
pp. 1017-1025 ◽  
Author(s):  
H Keppler ◽  
S Degeest ◽  
I Dhooge

AbstractObjectives:Chronic tinnitus is associated with reduced auditory input, which results in changes in the central auditory system. This study aimed to examine the relationship between tinnitus pitch and parameters of audiometry and distortion product otoacoustic emissions. For audiometry, the parameters represented the edge frequency of hearing loss, the frequency of maximum hearing loss and the frequency range of hearing loss. For distortion product otoacoustic emissions, the parameters were the frequency of lowest distortion product otoacoustic emission amplitudes and the frequency range of reduced distortion product otoacoustic emissions.Method:Sixty-seven patients (45 males, 22 females) with subjective chronic tinnitus, aged 18 to 73 years, were included.Results:No correlation was found between tinnitus pitch and parameters of audiometry and distortion product otoacoustic emissions. However, tinnitus pitch fell mostly within the frequency range of hearing loss.Conclusion:The current study seems to confirm the relationship between tinnitus pitch and the frequency range of hearing loss, thus supporting the homeostatic plasticity model.


2021 ◽  
Vol 13 ◽  
Author(s):  
Leslie K. Climer ◽  
Aubrey J. Hornak ◽  
Kaitlin Murtha ◽  
Yang Yang ◽  
Andrew M. Cox ◽  
...  

Ca2+ signaling is a major contributor to sensory hair cell function in the cochlea. Oncomodulin (OCM) is a Ca2+ binding protein (CaBP) preferentially expressed in outer hair cells (OHCs) of the cochlea and few other specialized cell types. Here, we expand on our previous reports and show that OCM delays hearing loss in mice of two different genetic backgrounds: CBA/CaJ and C57Bl/6J. In both backgrounds, genetic disruption of Ocm leads to early progressive hearing loss as measured by auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE). In both strains, loss of Ocm reduced hearing across lifetime (hearing span) by more than 50% relative to wild type (WT). Even though the two WT strains have very different hearing spans, OCM plays a considerable and similar role within their genetic environment to regulate hearing function. The accelerated age-related hearing loss (ARHL) of the Ocm KO illustrates the importance of Ca2+ signaling in maintaining hearing health. Manipulation of OCM and Ca2+ signaling may reveal important clues to the systems of function/dysfunction that lead to ARHL.


2015 ◽  
Vol 44 (2) ◽  
pp. 96 ◽  
Author(s):  
Raden Mohamad Krisna Barata ◽  
Muhammad Thaufiq Siddiq Boesoirie ◽  
Ratna Anggraeni Soepardi Poerwana

Latar belakang: Kemoterapi sisplatin adalah terapi yang sering diberikan untuk penderita tumor ganas yang mempunyai efek samping ototoksik dengan terbentuknya radikal bebas yang enyebabkan kematian sel rambut luar koklea sehingga terjadi gangguan dengar. Ginkgo biloba adalah antioksidan yang terbukti memiliki efek otoprotektif terhadap ototoksisitas akibat sisplatin dengan menghambat pembentukan radikal bebas. Tujuan: Mengetahui peran Ginkgo biloba terhadap pencegahan gangguan dengar sensorineural pada penderita tumor ganas dengan sisplatin. Metode: Penelitian ini merupakan penelitian uji klinis acak dengan sampel adalah semua penderita tumor ganas yang mendapat kemoterapi sisplatin di Rumah Sakit Hasan Sadikin pada bulan Oktober 2013 sampai Januari 2014. Sampel dibagi dua, kelompok perlakuan menjalani pengobatan kemoterapi sisplatin dengan tambahan ekstrak Ginkgo biloba (Egb 761) peroral 80 mg perhari sejak 1 hari sebelum kemoterapi selama 30 hari. Kelompok kontrol menjalani pengobatan kemoterapi sisplatin saja. Pemeriksaan fungsi pendengaran dilakukan dengan timpanometri, audiometri, dan Distortion Product Otoacoustic Emission (DPOAE) sebelum dan setelah kemoterapi sisplatin siklus pertama dan kedua. Hasil: Didapatkan total 40 data dari 20 pasien yang dibagi dalam dua kelompok. Kejadian gangguan dengar sensorineural setelah siklus pertama dengan pemeriksaan DPOAE didapatkan perbedaan yang bermakna (p=0,027). Kesimpulan: Pemberian terapi ekstrak Ginkgo biloba 80 mg peroral dapat mencegah gangguan dengar sensorineural akibat kemoterapi sisplatin pada penderita tumor ganas. Kata kunci: Sisplatin, Ginkgo biloba, ototoksik, gangguan dengar sensorineural, tumor ganas.ABSTRACTBackground: Chemotherapy with cisplatin is a treatment which often given to patients with malignant tumors with side effects of ototoxicity due to the formation of free radicals that caused cochlea outer hair cells death, causing hearing impairment. Ginkgo biloba is an antioxidant with otoprotective effect to cisplatin induced ototoxicity by inhibiting the formation of free radicals. Purpose:To find out the role of Ginkgo biloba against sensorineural hearing loss in patients with malignant tumors treated with cisplatin. Methods: This is a quasiexperimental clinical trial. The subject were all patients with malignant tumors who received cisplatin chemotherapy in Hasan Sadikin Hospital from October 2013 until January 2014. Sample was divided into 2 groups, the first group (treatment) are those who undergoing cisplatin chemotherapy treatment with additional Ginkgo biloba extract (EGb 761) 80 mg per day orally, started from 1 day prior chemotherapy for 30 days. The second group (control) is those who underwnet only cisplatin chemotherapy. Auditory function were assesed by tympanometry, audiometry and Distortion Product Otoacoustic Emission (DPOAE) examination before and after the first and second cycles cisplatin chemotherapy. Result: The data from right and left ear were analyzed separately, giving total 40 data from 20 patients divided in 2 groups. The incidence of sensorineural hearing loss after first cycle of chemotherapy with the DPOAE results showed significant differencess (p=0,027). Conclusion: Ginkgo biloba extract 80 mg perday orally could prevent cisplatin-induced ototoxicity in patients with malignancy. Keywords: Cisplatin, Ginkgo biloba, ototoxic, sensorineural hearing loss, malignant tumors.


Sign in / Sign up

Export Citation Format

Share Document